|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
36,651,000 |
Market
Cap: |
570.29(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$11.84 - $28.66 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
Total People Bought |
0 |
0 |
1 |
7 |
Total Buy Transactions |
0 |
0 |
1 |
8 |
Total Shares Sold |
2,500 |
5,000 |
5,000 |
10,265 |
Total Sell Value |
$60,025 |
$119,770 |
$119,770 |
$214,084 |
Total People Sold |
1 |
1 |
1 |
5 |
Total Sell Transactions |
2 |
4 |
4 |
15 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Madaus Martin D |
|
|
2020-11-04 |
4 |
OE |
$2.28 |
$3,648 |
D/D |
1,600 |
13,316 |
|
- |
|
Fry John J |
General Counsel & Secretary |
|
2020-11-02 |
4 |
S |
$36.97 |
$5,250 |
D/D |
(142) |
31,085 |
|
-65% |
|
Mattoon Dawn |
Sr. VP, Research Products |
|
2020-11-02 |
4 |
S |
$36.97 |
$5,878 |
D/D |
(159) |
31,344 |
|
-65% |
|
Hrusovsky E Kevin |
Chairman, President & CEO |
|
2020-11-02 |
4 |
AS |
$36.97 |
$120,666 |
D/D |
(3,264) |
1,028,534 |
|
65% |
|
Roskey Mark T. |
SVP, Commercial & Accelerator |
|
2020-11-02 |
4 |
S |
$36.97 |
$3,364 |
D/D |
(91) |
21,188 |
|
-65% |
|
Chaubal Amol |
Chief Financial Officer |
|
2020-11-02 |
4 |
S |
$36.97 |
$4,288 |
D/D |
(116) |
25,261 |
|
-65% |
|
Hrusovsky E Kevin |
Chairman, President & CEO |
|
2020-10-29 |
4 |
AS |
$38.30 |
$76,600 |
D/D |
(2,000) |
1,031,798 |
|
68% |
|
Madaus Martin D |
|
|
2020-10-20 |
4 |
AS |
$42.57 |
$68,112 |
D/D |
(1,600) |
11,716 |
|
88% |
|
Madaus Martin D |
|
|
2020-10-20 |
4 |
OE |
$2.28 |
$3,648 |
D/D |
1,600 |
13,316 |
|
- |
|
Madaus Martin D |
|
|
2020-10-19 |
4 |
AS |
$44.59 |
$71,344 |
D/D |
(1,600) |
11,716 |
|
94% |
|
Madaus Martin D |
|
|
2020-10-19 |
4 |
OE |
$2.28 |
$3,648 |
D/D |
1,600 |
13,316 |
|
- |
|
Duffy David C. |
SVP R&D and CTO |
|
2020-10-16 |
4 |
AS |
$43.04 |
$71,748 |
D/D |
(1,667) |
42,844 |
|
79% |
|
Hrusovsky E Kevin |
Chairman, President & CEO |
|
2020-10-13 |
4 |
AS |
$44.49 |
$88,980 |
D/D |
(2,000) |
1,033,798 |
|
76% |
|
Madaus Martin D |
|
|
2020-10-07 |
4 |
AS |
$37.17 |
$59,472 |
D/D |
(1,600) |
11,716 |
|
102% |
|
Madaus Martin D |
|
|
2020-10-07 |
4 |
OE |
$2.28 |
$3,648 |
D/D |
1,600 |
13,316 |
|
- |
|
Madaus Martin D |
|
|
2020-10-06 |
4 |
AS |
$36.47 |
$58,357 |
D/D |
(1,600) |
11,716 |
|
131% |
|
Madaus Martin D |
|
|
2020-10-06 |
4 |
OE |
$2.28 |
$3,648 |
D/D |
1,600 |
13,316 |
|
- |
|
Hrusovsky E Kevin |
Chairman, President & CEO |
|
2020-10-05 |
4 |
AS |
$33.90 |
$67,800 |
D/D |
(2,000) |
1,035,798 |
|
147% |
|
Madaus Martin D |
|
|
2020-10-01 |
4 |
A |
$34.70 |
$18,044 |
D/D |
520 |
11,716 |
|
- |
|
Mcconnell Sarah H |
|
|
2020-10-01 |
4 |
A |
$34.70 |
$9,994 |
D/D |
288 |
8,729 |
|
- |
|
Crandell Keith |
|
|
2020-10-01 |
4 |
A |
$34.70 |
$11,729 |
D/D |
338 |
10,071 |
|
- |
|
Meister Paul M |
|
|
2020-10-01 |
4 |
A |
$34.70 |
$13,741 |
D/D |
396 |
10,626 |
|
- |
|
Roskey Mark T. |
SVP, Commercial & Accelerator |
|
2020-10-01 |
4 |
S |
$34.12 |
$3,139 |
D/D |
(92) |
21,279 |
|
-133% |
|
Mattoon Dawn |
Sr. VP, Research Products |
|
2020-10-01 |
4 |
S |
$34.12 |
$5,425 |
D/D |
(159) |
31,503 |
|
-133% |
|
Fry John J |
General Counsel & Secretary |
|
2020-10-01 |
4 |
S |
$34.12 |
$4,880 |
D/D |
(143) |
31,227 |
|
-133% |
|
278 Records found
|
|
Page 10 of 12 |
|
|